ArticleBMC gastroenterology2021

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.

Rongrui Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.